Beranda › Kanker Paru Non-Sel Kecil › North Carolina › Winston-Salem
Uji klinis Kanker Paru Non-Sel Kecil di Winston-Salem, NC
12 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Winston-Salem (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi jauhnya
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Menerima pesertaFase 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Menerima pesertaFase 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Menerima pesertaFase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Menerima pesertaFase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Menerima pesertaFase 3
- Atrium Health Wake Forest Baptist, Winston-Salem
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
Menerima pesertaStudi observasional
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Menerima pesertaFase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Wake Forest NCORP Research Base, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Winston-Salem
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Winston-Salem
- Kanker (semua jenis)19 studi
- Leukemia Mieloid Akut18 studi
- Mieloma Multipel14 studi
- Kanker Payudara14 studi
- Penyakit Kardiovaskular14 studi
- PPOK10 studi
- Kanker Ovarium10 studi
- Diabetes Tipe 29 studi
- Sindrom Mielodisplastik9 studi
- Glioblastoma8 studi
- Leukemia Limfositik Kronis8 studi
- Kanker Paru8 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.